Myriad Genetics, Inc. (MYGN)

19,97 +0,50 (+2,57 %) À la clôture : 04:00PM EDT

Myriad Genetics, Inc.

322 North 2200 West
Salt Lake City, UT 84116
United States
801 584 3600
https://www.myriad.com

Secteur(s): Healthcare
Secteur d’activité: Diagnostics & Research
Employés à temps plein: 2 700

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Paul J. Diaz	CEO, President & Director	2,31M	S.O.	1962
Mr. Samraat S. Raha	Chief Operating Officer	514,76k	S.O.	1973
Dr. Dale Muzzey Ph.D.	Chief Scientific Officer	816,5k	S.O.	1980
Mr. Mark S. Verratti	Chief Commercial Officer	915,81k	S.O.	1968
Mr. Scott J. Leffler	Chief Financial Officer	S.O.	S.O.	1975
Ms. Natalie Munk	Principal Accounting Officer	S.O.	S.O.	1981
Dr. Kevin Richard Haas Ph.D.	Chief Technology Officer	580,36k	S.O.	1986
Mr. Matthew Scalo	Senior Vice President of Investor Relations	S.O.	S.O.	S.O.
Mr. Glenn Farrell	Senior VP & Chief Marketing Officer	S.O.	S.O.	S.O.
Ms. Shereen Solaiman	Chief People Officer	S.O.	S.O.	1973

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Myriad Genetics, Inc. en date du 1 mai 2024 est 5. Les scores principaux sont Audit : 10; Société : 1; Droits des actionnaires : 5; Compensation : 4.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.